Previous 10 | Next 10 |
home / stock / bhc:cc / bhc:cc news
Salix to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESSWIRE / February 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced the opening of the 2023 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 e...
LAVAL, QC / ACCESSWIRE / February 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and pro...
The healthcare sector has performed poorly in recent years, including the COVID year in 2020. Surprisingly, as of this writing, it outperforms all sectors with its 11.95% year-to-date gain. A reversal of fortune might be on the horizon, especially for growth stocks like Bausch Health Co...
In 2022, it was a healthy, uplifting year for some segments of the TSX. It was simply brutal for others, though some of the most aggressively beaten-down stocks carried that pattern over from the previous years. The question is, will 2023 be the year of their redemption? Because if it is, you can...
Summary Bausch Health is something of a basket case of a business. The company is still dealing with the fallout of the massive levels of debt taken on to buy underperforming companies under its former name, Valeant. Bausch is attempting to downsize and restructure debt - it spun of...
Bausch Health Companies ( NYSE: BHC ) said its new topical therapy Arazlo for acne vulgaris is now available to patients through the provincial public drug plans of Quebec, Ontario, Alberta and Saskatchewan, and the federal government's Non-Insured Health Benefits (NIHB) dr...
First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans Canada NewsWire LAVAL, QC , Dec. 22, 2022 /CNW Telbec/ - B...
Summary Shares of Bausch Health are down over 70% this year. Underwhelming earnings and developments around the Xifaxan patent have been the primary drivers of underperformance vs. the broader equity market. However, Bausch Health expects its Xifaxan patent to hinder generic entry i...
LAVAL, QB / ACCESSWIRE / December 2, 2022 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced that the US District Court for the District of New Jersey issued a favorable decision regarding DUOBRII® and BRYHALI®, in a suit filed against Padagis Israel Pharmaceuticals LTD and ...
Launching in December for Constipation Awareness Month, Initiatives Include Partnerships with Well-Known Lifestyle and Health Care Practitioner Influencers Campaign Coincides with Salix's Continued Support of Advocacy Groups Building Innovative Patient Education Programs and Advancing Diseas...
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC:CC Stock Symbol:
TSXC Market:
Bausch Health Companies Inc. Website:
LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT). Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 ...
LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business...
The S&P 500 rose to a new high on Friday, putting the broad-market index on track for yet another weekly gain during the holiday-shortened trading week. The tech-heavy NASDAQ Composite also hit a new high. The Dow Jones Industrials climbed 67.87 points to end Friday at 39,375.87. The ...